Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension

British Journal of Pharmacology

Volumn 160, Issue 1, 2010, Pages 77-87

  Ceron, C S ^a   Castro, M M ^a   Rizzi, E ^a   Montenegro, M F ^a   Fontana, V ^a   Salgado, M C O ^a   Gerlach, R F ^a   Tanus Santos, J E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hydrochlorothiazide; Matrix metalloproteinases; Reactive oxygen species; Renovascular hypertension; Spironolactone

Indexed keywords

GELATINASE A; HYDROCHLOROTHIAZIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIRONOLACTONE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLUOROMETRY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR RING; WISTAR RAT; ZYMOGRAPHY;

ANIMALS; ANTIOXIDANTS; AORTA; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HYDROCHLOROTHIAZIDE; HYPERTENSION, RENOVASCULAR; LIPID PEROXIDES; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; SPIRONOLACTONE; VASODILATION;

EID: 77950930269     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00678.x     Document Type: Article

References (56)

1. Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P (2005). Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 : 432 437. (Pubitemid 40315814)
2. Burla AK, Neves MF, Oigman W, Mandarim-de-Lacerda CA (2007). Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. Int J Cardiol 114 : 64 70. (Pubitemid 44802887)
3. Calder JA, Schachter M, Sever PS (1992). Direct vascular actions of hydrochlorothiazide and indapamide in isolated small vessels. Eur J Pharmacol 220 : 19 26.
4. Calder JA, Schachter M, Sever PS (1993). Ion channel involvement in the acute vascular effects of thiazide diuretics and related compounds. J Pharmacol Exp Ther 265 : 1175 1180. (Pubitemid 23321016)
5. Calder JA, Schachter M, Sever PS (1994). Vasorelaxant actions of 5-OH-indapamide, a major metabolite of indapamide: comparison with indapamide, hydrochlorothiazide and cicletanine. Eur J Pharmacol 256 : 185 191. (Pubitemid 24124945)
6. Cao J, Sato H, Takino T, Seiki M (1995). The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 270 : 801 805.
7. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL et al. (2008). Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 : 320 331. (Pubitemid 351707391)
8. Castro MM, Rizzi E, Rodrigues GJ, Ceron CS, Bendhack LM, Gerlach RF et al. (2009). Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic Biol Med 46 : 1298 1307.
9. Chesler NC, Ku DN, Galis ZS (1999). Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol 277 : H2002 H2009.
10. Contard F, Sabri A, Glukhova M, Sartore S, Marotte F, Pomies JP et al. (1993). Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats. Hypertension 22 : 665 676. (Pubitemid 23326213)
11. Dao HH, Lemay J, de Champlain J, deBlois D, Moreau P (2001). Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 19 : 1965 1973. (Pubitemid 33035801)
12. Di Zhang A, Cat AN, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S et al. (2008). Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension 52 : 1060 1067.
13. Fernandez-Patron C, Radomski MW, Davidge ST (1999). Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 : 906 911. (Pubitemid 29534165)
14. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST (2000). Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 : 670 676.
15. Fu X, Parks WC, Heinecke JW (2008). Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 19 : 2 13. (Pubitemid 350235984)
16. Griendling KK, Sorescu D, Ushio-Fukai M (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86 : 494 501. (Pubitemid 30165039)
17. Hao L, Nishimura T, Wo H, Fernandez-Patron C (2006). Vascular responses to alpha1-adrenergic receptors in small rat mesenteric arteries depend on mitochondrial reactive oxygen species. Arterioscler Thromb Vasc Biol 26 : 819 825. (Pubitemid 43732157)
18. de las Heras N, Ruiz-Ortega M, Miana M, Ruperez M, Sanz-Rosa D, Aragoncillo P et al. (2007). Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 25 : 629 638. (Pubitemid 46213802)
19. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K et al. (2008). Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51 : 211 217. (Pubitemid 351159930)
20. Intengan HD, Schiffrin EL (2001). Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38 : 581 587.
21. Jaffe IZ, Mendelsohn ME (2005). Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 96 : 643 650.
22. Jaffe IZ, Tintut Y, Newfell BG, Demer LL, Mendelsohn ME (2007). Mineralocorticoid receptor activation promotes vascular cell calcification. Arterioscler Thromb Vasc Biol 27 : 799 805. (Pubitemid 46606709)
23. Janiszewski M, Souza HP, Liu X, Pedro MA, Zweier JL, Laurindo FR (2002). Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts. Free Radic Biol Med 32 : 446 453.
24. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM (2006). Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. Faseb J 20 : 1546 1548.
25. Knight JA, Pieper RK, McClellan L (1988). Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation. Clin Chem 34 : 2433 2438.
26. Koenig W, Binner L, Gabrielsen F, Sund M, Rosenthal J, Hombach V (1991). Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension. J Cardiovasc Pharmacol 18 : 349 353.
27. Lerman LO, Chade AR, Sica V, Napoli C (2005). Animal models of hypertension: an overview. J Lab Clin Med 146 : 160 173.
28. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG et al. (2004). Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383 : 413 418.
29. Martinez ML, Lopes LF, Coelho EB, Nobre F, Rocha JB, Gerlach RF et al. (2006). Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 47 : 117 122.
30. Martinez ML, Castro MM, Rizzi E, Fernandes K, Demacq C, Bendhack LM et al. (2008). Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur J Pharmacol 591 : 224 230.
31. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M (2005). Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 97 : 434 442.
32. Mougenot N, Mediani O, Lechat P (2005). Bisoprolol and hydrochlorothiazide effects on cardiovascular remodeling in spontaneously hypertensive rats. Pharmacol Res 51 : 359 365.
33. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H (2005). Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 28 : 925 936.
34. Nobre F, da Silva CA, Coelho EB, Salgado HC, Fazan R Jr. (2006). Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. Am J Hypertens 19 : 1079 1083.
35. Oliveira-Sales EB, Dugaich AP, Carillo BA, Abreu NP, Boim MA, Martins PJ et al. (2008). Oxidative stress contributes to renovascular hypertension. Am J Hypertens 21 : 98 104.
36. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL (2003). Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42 : 49 55.
37. Rabkin SW (1993). Comparison of indapamide and hydrochlorothiazide on spontaneous contraction of cardiomyocytes in culture: the effect on alterations of extracellular calcium or potassium. Gen Pharmacol 24 : 699 704.
38. Rizzi E, Castro MM, Fernandes K, Barbosa F Jr., Arisi GM, Garcia-Cairasco N et al. (2009). Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. Arch Toxicol 83 : 439 449.
39. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS et al. (2005). Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension 46 : 555 561.
40. Rueckschloss U, Duerrschmidt N, Morawietz H (2003). NADPH oxidase in endothelial cells: impact on atherosclerosis. Antioxid Redox Signal 5 : 171 180.
41. Safar ME, London GM, Asmar R, Frohlich ED (1998). Recent advances on large arteries in hypertension. Hypertension 32 : 156 161.
42. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I et al. (2007). Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 50 : 919 925.
43. Schulz R (2007). Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47 : 211 242.
44. Sladkova M, Kojsova S, Jendekova L, Pechanova O (2007). Chronic and acute effects of different antihypertensive drugs on femoral artery relaxation of l-NAME hypertensive rats. Physiol Res 56 (Suppl 2 S85 S91.
45. Sonder SU, Mikkelsen M, Rieneck K, Hedegaard CJ, Bendtzen K (2006). Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction. Br J Pharmacol 148 : 46 53.
46. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S (2006). Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12 : 240 245.
47. Touyz RM, Schiffrin EL (2004). Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122 : 339 352.
48. Touyz RM, Tabet F, Schiffrin EL (2003). Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30 : 860 866.
49. Valenzuela A (1991). The biological significance of malondialdehyde determination in the assessment of tissue oxidative stress. Life Sci 48 : 301 309.
50. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL (2008). Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 295 : H281 H288.
51. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002). Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 : 504 510.
52. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S et al. (2009). Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 119 : 2480 2489.
53. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M et al. (1999). Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 : 2027 2033.
54. Xiao F, Puddefoot JR, Vinson GP (2000). Aldosterone mediates angiotensin II-stimulated rat vascular smooth muscle cell proliferation. J Endocrinol 165 : 533 536.
55. 2 in angiotensin II-induced vascular hypertrophy. Hypertension 32 : 488 495.
56. Zhu Z, Zhu S, Liu D, Cao T, Wang L, Tepel M (2005). Thiazide-like diuretics attenuate agonist-induced vasoconstriction by calcium desensitization linked to Rho kinase. Hypertension 45 : 233 239.